Found: 106
Select item for more details and to access through your institution.
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected.
- Published in:
- EMBO Molecular Medicine, 2020, v. 12, n. 12, p. 1, doi. 10.15252/emmm.202012921
- By:
- Publication type:
- Article
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
- Published in:
- Brain: A Journal of Neurology, 2023, v. 146, n. 4, p. 1592, doi. 10.1093/brain/awac333
- By:
- Publication type:
- Article
Performance testing of a novel GFAP ELISA for CSF and blood based matrices.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082999
- By:
- Publication type:
- Article
Performance of optimized prototype LUMIPULSE G immunoassays for plasma pTau181 and pTau217.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082944
- By:
- Publication type:
- Article
Preliminary performance of the Lumipulse G pTau 217 Plasma prototype assay on plasma samples.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.079647
- By:
- Publication type:
- Article
Performance of plasma pTau181 and pTau217 measured with fully automated LUMIPULSE G prototype immunoassays.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.079533
- By:
- Publication type:
- Article
Profiling amyloid‐β peptides as diagnostic biomarkers for cerebral amyloid angiopathy.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.076080
- By:
- Publication type:
- Article
Plasma ALZpath p‐tau217 for the identification of amyloid and tau positivity.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.079892
- By:
- Publication type:
- Article
Plasma phosphorylated tau 217 levels are highly stable under common pre‐analytical sample handling procedures.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.078393
- By:
- Publication type:
- Article
Cross‐sectional investigation of synaptic markers Neurogranin and BACE1 in CSF from the AIBL study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.078048
- By:
- Publication type:
- Article
Point of care measurement of blood tau in Alzheimer's dementia.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.067530
- By:
- Publication type:
- Article
Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 5, p. 1913, doi. 10.1002/alz.12841
- By:
- Publication type:
- Article
A head‐to‐head comparison of plasma phosphorylated tau assays in the real‐world memory clinic.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 6, p. 1, doi. 10.1002/alz.065391
- By:
- Publication type:
- Article
CSF‐plasma biomarker profiles from BioFINDER MCI patients using the same technology.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 6, p. 1, doi. 10.1002/alz.064456
- By:
- Publication type:
- Article
Plasma pTau181/Aβ42 identifies cognitive change earlier than CSF pTau181/Ab42.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 6, p. 1, doi. 10.1002/alz.064341
- By:
- Publication type:
- Article
Value of plasma biomarkers to predict memory change in cognitively unimpaired individuals.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 6, p. 1, doi. 10.1002/alz.061795
- By:
- Publication type:
- Article
The effects of age and sex on plasma p‐tau181 concentrations in Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 5, p. 1, doi. 10.1002/alz.068159
- By:
- Publication type:
- Article
Plasma p‐tau181 concentration accurately predicts clinically diagnosed Alzheimer's Disease cases.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 5, p. 1, doi. 10.1002/alz.068059
- By:
- Publication type:
- Article
Predictive value of a plasma p‐tau181‐specific assay for amyloid accumulation in asymptomatic Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 5, p. 1, doi. 10.1002/alz.061421
- By:
- Publication type:
- Article
Amyloid‐βeta peptides in CSF and plasma discriminate cerebral amyloid angiopathy from controls.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.053858
- By:
- Publication type:
- Article
Development and analytical characterization of novel tau Simoa assays targeting full‐length tau in CSF and mid‐tau in CSF and plasma.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.054911
- By:
- Publication type:
- Article
Development and analytical performance testing of a novel sTREM2 ELISA method to support drug development.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.054868
- By:
- Publication type:
- Article
Distinctive effect of biological sex in AD‐related CSF and plasma biomarkers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.052959
- By:
- Publication type:
- Article
Plasma P‐tau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.051727
- By:
- Publication type:
- Article
Cerebrospinal fluid biomarker levels are not affected by aspiration or gravity drip extraction methods in Alzheimer's disease: The AIBL study: Biomarkers (non‐neuroimaging): Method development and validation.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.046703
- By:
- Publication type:
- Article
Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals: Biomarkers (non‐neuroimaging): Blood based biomarkers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.045470
- By:
- Publication type:
- Article
Comparison of two analytical platforms for blood‐based surrogate biomarkers of amyloid pathology: Biomarkers (non‐neuroimaging) / plasma/serum/urine biomarkers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.045110
- By:
- Publication type:
- Article
Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1‐42, Aβ1‐40, GFAP and NF‐L in blood: Biomarkers (non‐neuroimaging) / plasma/serum/urine biomarkers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.043506
- By:
- Publication type:
- Article
Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology: Biomarkers (non‐neuroimaging): Longitudinal and prognostic biomarker studies.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.041849
- By:
- Publication type:
- Article
Amyloid, pTau, NfL, and GFAP as biomarkers for Alzheimer's disease: Clinical study results of AD blood biomarkers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.038179
- By:
- Publication type:
- Article
O2‐05‐03: CHARACTERIZATION AND TRANSFER OF A NOVEL PLASMA Aβ1‐42/Aβ1‐40 SIMOA ASSAY FOR INTEGRATION INTO THE CLINIC.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P546, doi. 10.1016/j.jalz.2019.06.4477
- By:
- Publication type:
- Article
F2‐07‐04: PLASMA AMYLOID BETA 1–42 AND 1–40 MEASURED BY A NOVEL SIMOA ASSAY AS A DIAGNOSTIC TOOL FOR ALZHEIMER'S DISEASE PATHOLOGY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P527, doi. 10.1016/j.jalz.2019.06.4443
- By:
- Publication type:
- Article
P1‐230: MEMORY FUNCTION IS ASSOCIATED WITH TAU PATHOLOGY IN PARKINSON'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P323, doi. 10.1016/j.jalz.2019.06.785
- By:
- Publication type:
- Article
F1‐05‐01: LAB‐RELATED PRE‐ANALYTICAL FACTORS INFLUENCING PLASMA AMYLOID BETA CONCENTRATIONS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P183, doi. 10.1016/j.jalz.2019.06.4385
- By:
- Publication type:
- Article
P3‐246: C‐REACTIVE PROTEIN, PLASMA AMYLOID BETA LEVELS AND MRI MARKERS: THE ROTTERDAM STUDY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1166, doi. 10.1016/j.jalz.2018.06.1605
- By:
- Publication type:
- Article
O3‐09‐06: A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1‐42 AND 1‐40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1039, doi. 10.1016/j.jalz.2018.06.2824
- By:
- Publication type:
- Article
O3‐09‐04: PLASMA AMYLOID β LEVELS, CEREBRAL ATROPHY AND DEMENTIA RISK: THE ROTTERDAM STUDY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1037, doi. 10.1016/j.jalz.2018.06.2822
- By:
- Publication type:
- Article
O2‐09‐04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α‐SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P642, doi. 10.1016/j.jalz.2018.06.2691
- By:
- Publication type:
- Article
P1‐273: EVALUATION OF CERTIFIED REFERENCE MATERIALS FOR BETA‐AMYLOID 1‐42 IN EUROIMMUN BETA‐AMYLOID 1‐42 ELISA AND CHLIA.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P387, doi. 10.1016/j.jalz.2018.06.279
- By:
- Publication type:
- Article
Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 6, p. 2931, doi. 10.3390/ijms22062931
- By:
- Publication type:
- Article
Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease.
- Published in:
- Translational Psychiatry, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41398-020-01137-1
- By:
- Publication type:
- Article
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.
- Published in:
- Alzheimer's Research & Therapy, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13195-020-00728-w
- By:
- Publication type:
- Article
Combination of plasma amyloid beta<sub>(1-42/1-40)</sub> and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology.
- Published in:
- Alzheimer's Research & Therapy, 2020, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13195-020-00682-7
- By:
- Publication type:
- Article
Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study.
- Published in:
- Alzheimer's Research & Therapy, 2018, v. 10, n. 1, p. N.PAG, doi. 10.1186/s13195-018-0395-6
- By:
- Publication type:
- Article
Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2016, v. 54, n. 7, p. 1177, doi. 10.1515/cclm-2015-0733
- By:
- Publication type:
- Article
A NOVEL COLORIMETRIC ELISA FOR QUANTIFICATION OF TAU, PHOSPHORYLATED AT THREONINE 181, IN CEREBROSPINAL FLUID.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P353, doi. 10.1016/j.jalz.2017.06.287
- By:
- Publication type:
- Article
PLASMA AMYLOID BETA LEVELS, CEREBRAL SMALL-VESSEL DISEASES AND COGNITION: THE ROTTERDAM STUDY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1035, doi. 10.1016/j.jalz.2017.06.1461
- By:
- Publication type:
- Article
THE CSF Aβ(1-42)/Aβ(1-40) RATIO IMPROVES THE CLINICAL UTILITY OF Aβ(1-42) BY ITS IMPACT AT ANALYTICAL AND CLINICAL LEVELS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P198, doi. 10.1016/j.jalz.2017.07.059
- By:
- Publication type:
- Article
ANALYTICAL PERFORMANCE CHARACTERISTICS OF A NOVEL IMMUNOASSAY FOR THE QUANTIFICATION OF BACE-1 IN HUMAN CEREBROSPINAL FLUID.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P357, doi. 10.1016/j.jalz.2017.06.296
- By:
- Publication type:
- Article
USE FOR CALIBRATION OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1512, doi. 10.1016/j.jalz.2017.07.630
- By:
- Publication type:
- Article